Overexpression of DJ-1 and HSP90α, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 507-512

  Lee, Hojung ^a   Choi, Seung Kyu ^a   Ro, Jae Y ^b  

^a Eulji University School of Medicine   (South Korea)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

DJ 1; HSP90 ; Pakt; PI3K p110a; PTEN; Urothelial carcinoma

Indexed keywords

DJ 1 PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P110; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 84862926469     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.522     Document Type: Article

References (41)

1. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T and Cordon-Cardo C: Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28: 401-408, 2010.
2. Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005.
3. Alessi DR, James SR, Downes CP, et al: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7: 261-269, 1997.
4. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
5. Di Cristofano A and Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 100: 387-390, 2000.
6. Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772, 2005.
7. Xu W and Neckers L: Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13: 1625-1629, 2007.
8. Millson SH, Truman AW, Racz A, et al: Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol. FEBS J 274: 4453-4463, 2007.
9. Solit DB, Ivy SP, Kopil C, et al: Phase I trial of 17-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13: 1775-1782, 2007.
10. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P and Rosen N: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277: 39858-39866, 2002.
11. Bonifati V, Rizzu P, Squitieri F, et al: DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24: 159-160, 2003.
12. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K and Ariga H: DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5: 213-218, 2004.
13. Kim RH, Peters M, Jang Y, et al: DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7: 263-273, 2005.
14. Yuen HF, Chan YP, Law S, et al: DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 17: 3593-3602, 2008.
15. Le Naour F, Misek DE, Krause MC, et al: Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7: 3328-3335, 2001.
16. Tian M, Cui YZ, Song GH, et al: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8: 241, 2008.
17. Knowles M A, Plat t F M, Ross R L a nd Hu r st C D: Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 28: 305-316, 2009.
18. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF and Knowles MA: AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 29: 150-155, 2010.
19. Lebret T, Watson RW, Molinie V, et al: Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 98: 970-977, 2003.
20. Cardillo MR, Sale P and Di Silverio F: Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 20: 4579-4583, 2000.
21. Ebele JN, Sauter G, Epstein JI and Sesterhenn IA (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, 2004.
22. Fan J, Ren H, Jia N, et al: DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem 283: 4022-4030, 2008.
23. Clements CM, McNally RS, Conti BJ, Mak TW and Ting JP: DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 103: 15091-15096, 2006.
24. Zhu XL, Wang ZF, Lei WB, Zhuang HW, Jiang HY and Wen WP: DJ-1: A novel independent prognostic marker for survival in glottis squamous cell carcinoma. Cancer Sci 101: 1320-1325, 2010.
25. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23: 675-680, 2009.
26. Harris LD, De La Cerda J, Tuziak T, et al: Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog 47: 678-685, 2008.
27. Schultz L, Albadine R, Hicks J, et al: Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 116: 5517-5526, 2010.
28. Lopez-Knowles E, Hernandez S, Malats N, et al: PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401-7404, 2006.
29. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P and Knowles MA: Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 15: 6008-6017, 2009.
30. Qian CN, Furge KA, Knol J, et al: Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res 69: 8256-8264, 2009.
31. Pantuck AJ, Seligson DB, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109: 2257-2267, 2007.
32. King JC, Xu J, Wongvipat J, et al: Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526, 2009.
33. Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H and Yuan J: Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res 66: 1929-1939, 2006.
34. Ramanathan RK, Egorin MJ, Erlichman C, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. JClin Oncol 28: 1520-1526, 2010.
35. Modi S, Stopeck A, Linden H, et al: HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 17: 5132-5139, 2011.
36. Pacey S, Wilson RH, Walton M, et al: A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17: 1561-1570, 2011.
37. Karkoulis PK, Stravopodis DJ, Margaritis LH and Voutsinas GE: 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 10: 481, 2010.
38. Li CF, Huang WW, Wu JM, et al: Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 14: 7822-7831, 2008.
39. Yang Y, Gehrke S, Haque ME, et al: Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 102: 13670-13675, 2005.
40. Georgescu MM: PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 1: 1170-1177, 2010.
41. Yuan TL and Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510, 2008.